crisaborole Side Effects
Also known as: Eucrisa
Analysis of 9,400 adverse event reports submitted to the FDA from 2013 to 2025.
Total Reports
9,400
Death-Related
24
0.3% of reports
Hospitalizations
142
1.5% of reports
Top Indication
Dermatitis Atopic
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 24 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 19 |
| OFF LABEL USE | 3 |
| ACCIDENTAL DEATH | 2 |
| BURNING SENSATION | 2 |
| CONDITION AGGRAVATED | 2 |
| PRURITUS | 2 |
| ACNE | 1 |
| APPLICATION SITE PAIN | 1 |
| APPLICATION SITE PRURITUS | 1 |
| ASTHMA | 1 |
| COMA | 1 |
| DEAFNESS UNILATERAL | 1 |
| DEMENTIA | 1 |
| DRUG EFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DRUG INEFFECTIVE | 1 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DYSPNOEA | 1 |
| ERYTHEMA | 1 |
| INFLAMMATION | 1 |
| NEOPLASM MALIGNANT | 1 |
Reactions in Hospitalization Reports
Top reactions in 142 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ECZEMA | 22 |
| OFF LABEL USE | 21 |
| PRURITUS | 20 |
| RASH | 20 |
| FATIGUE | 18 |
| ERYTHEMA | 16 |
| CONDITION AGGRAVATED | 15 |
| ARTHRALGIA | 14 |
| DRUG HYPERSENSITIVITY | 14 |
| NASOPHARYNGITIS | 14 |
| PYREXIA | 14 |
| CHEST PAIN | 13 |
| PAIN | 13 |
| UPPER RESPIRATORY TRACT INFECTION | 13 |
| CELLULITIS | 12 |
| NAUSEA | 12 |
| PAIN IN EXTREMITY | 12 |
| URINARY TRACT INFECTION | 12 |
| DRUG INEFFECTIVE | 11 |
| HYPERSENSITIVITY | 11 |
Nearby — Related Medications
What the FAERS Data Reveals About crisaborole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 9,400 voluntary reports linked to crisaborole and its brand equivalents (Eucrisa), spanning 2013 through 2025. Of those, 24 (0.3%) listed death as an outcome and 142 (1.5%) involved hospitalization. The most common indication reported alongside adverse events was Dermatitis Atopic.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 65% were female and 35% male; age distribution skews toward 0-17, with 2,166 reports in that bracket. The single most reported reaction is drug ineffective with 1,957 submissions, followed by application site pain and burning sensation.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.